Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models.

Henning HvidChristian L BrandTina HummelshøjSanne JensenStephan D BoumanAndrew BowlerBjarne R PoulsenPeter TiainenThorbjörn ÅkertrömDamien DemozayThomas Hoeg-JensenCamilla IngvorsenThomas Å PedersenJim McGuireThomas EgebjergKaren A CappelenIna P EliasenBo F HansenStephanie HennenCarsten E StidsenGrith S OlsenNikolaj Kulahin Roed

Published in: Diabetologia (2022)

While the dual-acting glucagon receptor inhibitor and liver-preferential insulin molecule showed markedly improved regulation of blood glucose, effects that are potential safety concerns persisted in the pharmacologically relevant dose range.

Keyphrases

glycemic control
blood glucose
type diabetes
mouse model
weight loss
insulin resistance
cardiovascular disease
high throughput
oxidative stress
stem cells
combination therapy
metabolic syndrome
binding protein
climate change
smoking cessation